[1]
Sholzberg, M., Gwathmey, K., Broome, C.M., Goebeler, M., Murai, H., Bata-Csörgo, Z., Newland, A., Ulrichts, P., Kerstens, R., Guptill, J.T., Agha, S., Jiang, M. and Howard Jr, J.F. 2024. Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases. SKIN The Journal of Cutaneous Medicine. 8, 1 (Jan. 2024), s344. DOI:https://doi.org/10.25251/skin.8.supp.344.